Autoimmune biopharmaceutical company Find Therapeutics has assembled a clinical advisory board to support its FTX-101 program.
The advisory board will consist of five physician leaders:
Douglas Arnold, MD, is a professor in the department of neurology and neurosurgery at McGill University in Montreal. He specializes in neuroimaging and multiple sclerosis drug therapy.
Jeffrey Cohen, MD, is a professor of neurology in the Cleveland Clinic Lerner College of Medicine. He is also a leader in clinical trial research for multiple sclerosis.
Jerome De Seze, MD, PhD, is a professor of neurology at the University Hospital of Strasbourg (France). He is also an immunology specialist.
Mark Freedman, MD, is a professor of neurology at the University of Ottawa (Canada). He conducts research in molecular neurochemistry and cellular immunology.
Maria Pia Sormani, PhD, is a professor of biostatistics at the University of Genoa (Italy). She is a leader in statistics for clinical trials.
"Their deep knowledge of complex underlying disease processes and their understanding of patient needs will be instrumental as we advance our autoimmune programs," Philippe Douville, CEO of Find Therapeutics, said in a Nov. 7 press release. "With the formation of our clinical advisory board, we have positioned ourselves to benefit from strategic insights from world leaders in demyelinating diseases."